Nanobiotix (NASDAQ:NBTX) Price Target Raised to $26.00 at Guggenheim

Nanobiotix (NASDAQ:NBTX) had its price target hoisted by Guggenheim from $8.00 to $26.00 in a report released on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other equities analysts have also commented on the company. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. TD Cowen began coverage on shares of Nanobiotix in a research report on Friday. They set a “buy” rating on the stock. Leerink Partners restated an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Nanobiotix has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Nanobiotix Price Performance

Shares of NBTX opened at $20.85 on Friday. Nanobiotix has a one year low of $2.95 and a one year high of $30.35. The business’s 50 day simple moving average is $21.64 and its 200-day simple moving average is $17.32.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. acquired a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.